NS

Nancy Saputra

IT Director, Security at Allogene Therapeutics

Nancy Saputra has a strong background in IT and security, with experience spanning over 30 years. Nancy currently holds the position of IT Director, Security at Allogene Therapeutics, where they have been since 2019. Prior to that, they served as the IT Director, Systems, Cloud, & Security. Before joining Allogene Therapeutics, Nancy worked at Toyota Research Institute as the Director, Information Systems Security from 2018 to 2019.

Nancy's longest tenure was at Rambus, where they worked for over 20 years in various managerial roles. Nancy served as the Senior Manager, IT Program Management & Security from 2012 to 2018. In this role, they led the IT Project Management Office (PMO) and operations, managing projects related to security, M&A's, site/data center build outs, and more. Nancy also formed a security incident response team and established related processes.

Before their time at Rambus, Nancy held managerial positions at Hyundai Electronics, Oracle, and IBM, where they gained experience in network analysis, UNIX systems administration, and technical leadership.

Overall, Nancy Saputra is a seasoned IT professional with expertise in security, systems, cloud, and program management. Their experience includes leading teams, managing projects, and establishing policies and guidelines.

Nancy Saputra completed their Bachelor of Science degree in Computer Science & Engineering from the University of California, Davis. In terms of additional certifications, they obtained a Microsoft Certified: Azure Fundamentals certification from Microsoft in August 2023. Nancy also acquired a Security, Compliance, and Identity Fundamentals certification from Microsoft in May 2022. Prior to that, Nancy earned a CCSP certification from (ISC)² in March 2018. In September 2016, they obtained an ISO/IEC 27001:2013 Lead Auditor (TPECS) certification from BSI. Nancy Saputra's earliest certification is a CISSP certification from (ISC)², which they acquired in July 2010.

Location

San Francisco, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Allogene Therapeutics

1 followers

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.


Industries

Employees

201-500

Links